### 1 CD4+ and CD8+ T cell and antibody correlates of protection against

## 2 Delta vaccine breakthrough infection: A nested case-control study

### 3 within the PITCH study

- 4 Isabel Neale<sup>1,2,3</sup>, Mohammad Ali<sup>1,2,3</sup>, Barbara Kronsteiner<sup>1,2</sup>, Stephanie Longet<sup>4,5</sup>,
- 5 Priyanka Abraham<sup>1,2</sup>, Alexandra S. Deeks<sup>1,6</sup>, Anthony Brown<sup>1</sup>, Shona C. Moore<sup>7</sup>,
- 6 Lizzie Stafford<sup>5</sup>, Susan L. Dobson<sup>7</sup>, Megan Plowright<sup>8,9</sup>, Thomas A.H. Newman<sup>8,9</sup>,
- 7 Mary Y Wu<sup>10</sup>, Crick COVID Immunity Pipeline<sup>10,11</sup>, Edward J Carr<sup>11</sup>, Rupert
- 8 Beale<sup>11,12</sup>, Ashley D Otter<sup>13</sup>, Susan Hopkins<sup>14</sup>, Victoria Hall<sup>14,15</sup>, Adriana
- 9 Tomic<sup>16,17,18,19</sup>, Rebecca P. Payne<sup>20</sup>, Eleanor Barnes<sup>1,6,21,22</sup>, Alex Richter<sup>23,24</sup>,
- 10 Christopher J.A. Duncan<sup>20,25</sup>, Lance Turtle<sup>7,26</sup>, Thushan I. de Silva<sup>8,9</sup>, Miles Carroll<sup>4,5</sup>,
- 11 Teresa Lambe<sup>19,27</sup>†, Paul Klenerman<sup>1,6,21,22</sup>†\* and Susanna Dunachie<sup>1,2,3,6</sup>†\* on
- 12 behalf of the PITCH Consortium
- Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical
   Medicine, University of Oxford, UK
- NDM Centre For Global Health Research, Nuffield Department of Clinical
   Medicine, University of Oxford, UK
- 17 3. Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand
- Pandemic Sciences Institute, Nuffield Department of Medicine, University of
   Oxford, UK
- Wellcome Centre for Human Genetics, Nuffield Department of Medicine,
   University of Oxford, UK
- 22 6. Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 23 7. NIHR Health Protection Research Unit in Emerging and Zoonotic Infections,
- Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool,
   UK
- 26 8. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
- Department of Infection, Immunity and Cardiovascular Disease, University of
   Sheffield, UK
- 29 10. Covid Surveillance Unit, The Francis Crick Institute, London, UK
- 30 11. The Francis Crick Institute, London, UK
- 31 12. UCL Department of Renal Medicine, Royal Free Hospital, London, UK
- 32 13. UK Health Security Agency, Porton Down, UK
- 33 14. UK Health Security Agency, London, SE1 8UG, UK
- 34 15. UK Health Security Agency, London, NW9 5EQ, UK
- 35 16. National Emerging Infectious Diseases Laboratories, Boston University, Boston,
   36 MA, USA
- 37 17. Department of Microbiology, Boston University School of Medicine, Boston, MA,38 USA
- 39 18. Department of Biomedical Engineering, Boston University, Boston, MA, USA
- 40 19. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford,
- 41 UK

- 42 20. Translational and Clinical Research Institute Immunity and Inflammation Theme,
- 43 Newcastle University, Newcastle, UK
- 44 21. Translational Gastroenterology Unit, University of Oxford, Oxford, UK
- 45 22. NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
- 46 23. Institute of Immunology and Immunotherapy, College of Medical and Dental
   47 Science, University of Birmingham, Birmingham, UK
- 48 24. University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 25. Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals
   NHS Foundation Trust, Newcastle, UK
- 51 26. Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK
- 52 27. Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University
   53 of Oxford, Oxford, UK
- 54 †Senior author
- 55 \*Corresponding authors:
- 56 Susanna Dunachie, Peter Medawar Building for Pathogen Research, University of
- 57 Oxford, OX1 3SY, UK. susie.dunachie@ndm.ox.ac.uk
- 58 Paul Klenerman, Peter Medawar Building for Pathogen Research, University of
- 59 Oxford, Oxford OX1 3SY, UK. paul.klenerman@ndm.ox.ac.uk
- 60 Secondary author list is included in the supplement.

#### 61 ABSTRACT

- 62 T cell correlates of protection against SARS-CoV-2 infection after vaccination
- 63 ('vaccine breakthrough') are incompletely defined, especially the specific
- 64 contributions of CD4+ and CD8+ T cells. We studied 279 volunteers in the Protective
- 65 Immunity from T Cells in Healthcare Workers (PITCH) UK study, including 32 cases
- 66 (with SARS-CoV-2 positive testing after two vaccine doses during the Delta-
- 67 dominant era) and 247 controls (no positive test nor anti-nucleocapsid
- 68 seroconversion during this period). 28 days after second vaccination, before all
- 69 breakthroughs occurred, cases had lower ancestral S- and RBD-specific
- 70 immunoglobulin G titres and S1- and S2-specific T cell interferon gamma (IFNy)
- 71 responses compared with controls. In a subset of matched cases and controls,
- 72 cases had lower CD4+ and CD8+ IFNγ and tumour necrosis factor responses to
- 73 Delta S peptides with reduced CD8+ responses to Delta versus ancestral peptides
- 74 compared with controls. Our findings support a protective role for T cells against
- 75 Delta breakthrough infection.

### 76 INTRODUCTION

- 77 Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
- 78 has been a crucial control strategy for the current COVID-19 pandemic. Although
- 79 new SARS-CoV-2 variants continue to emerge and cause infection, vaccine
- 80 protection against severe COVID-19 remains high for otherwise healthy individuals
- 81 (Collie et al., 2022; Tartof et al., 2021). Nonetheless, infection or re-infection after a
- 82 two-dose primary vaccination course, so-called 'vaccine breakthrough', occurred
- 83 during the emergence and spread of variants of concern (VOC). As a result, booster
- 84 (third) doses have been made available to all adults in many countries including the
- 85 UK (UK Health Security Agency, 2022).
- 86 Understanding correlates of protection (CoP) against infection with SARS-CoV-2
- 87 could optimise delivery of current vaccines by informing boosting schedules and
- 88 identifying individuals with suboptimal responses to vaccination. Identification of CoP
- 89 could further facilitate licencing of modified or new vaccines based on
- 90 immunogenicity and safety data rather than efficacy data (Feng et al., 2021),
- 91 allowing new vaccines to more readily enter the marketplace.

92 Evidence supports a number of humoral correlates of protection against infection 93 with SARS-CoV-2. Neutralising antibody (NAb) titres after vaccination correlate with 94 vaccine efficacy and protection from infection in trials (Earle et al., 2021; Feng et al., 95 2021; Gilbert et al., 2022; Khoury et al., 2021) and NAbs from prior infection with 96 ancestral variant are associated with protection against infection with ancestral 97 (Addetia et al., 2020) and Alpha (Atti et al., 2022) variants. NAbs against SARS-CoV-98 2 are lower in the peri-infection period in those who experience Alpha vaccine 99 breakthrough (Bergwerk et al., 2021), and are lower at diagnosis in those who 100 experience Delta vaccine breakthrough (Chau et al., 2021) compared with uninfected 101 controls. Anti-ancestral spike (S) and receptor binding domain (RBD) 102 immunoglobulin G (IgG) titres also correlate with protection from infection with the 103 Alpha variant (Feng et al., 2021) and Delta variant (Aldridge et al., 2022; Smoot et 104 al., 2022; Wei et al., 2022) after vaccination. Ancestral variant RBD-specific memory 105 B cell responses were lower in Delta breakthrough cases at the point of diagnosis 106 compared to uninfected close contacts (Tay et al., 2022). Levels of serum anti-Spike 107 and anti-RBD IgA 2-4 weeks after second dose of BNT162b2 vaccine were also 108 lower in those who experienced subsequent Alpha or Gamma vaccine breakthrough 109 compared to those who remained uninfected (Sheikh-Mohamed et al., 2022).

T cells play an important role in control of SARS-CoV-2 infection and in reducing
disease severity upon infection (Kedzierska and Thomas, 2022; Moss, 2022). In
primary infection, strong SARS-CoV-2 specific CD4+ and CD8+ T cell responses are
associated with reduced disease severity (Rydyznski Moderbacher et al., 2020).
Several studies have demonstrated that spike-specific T cell responses are largely

maintained against VOC (Gao et al., 2022; Moore et al., 2022; Payne et al., 2021;

Skelly et al., 2021; Tarke et al., 2022), despite evasion of antibody responses (Cele

117 et al., 2022; Planas et al., 2021; Zhou et al., 2021). This supports T cells contributing

118 to the continued effectiveness of vaccines against severe disease.

119 However, identifying a clear role for T cells in preventing infection is difficult due to 120 the lack of sensitive, scalable T cell assays, and potential confounding effects of 121 antibody responses (Kedzierska and Thomas, 2022; Kent et al., 2022). Nonetheless, 122 an increasing number of reports indicate that T cells are likely to be important in 123 protection against SARS-CoV-2 infection. Unvaccinated individuals who are exposed 124 to SARS-CoV-2 but remain antibody and PCR-negative show T cell responses 125 (Ogbe et al., 2021), and further studies demonstrate that pre-existing, cross-reactive 126 T cell responses are associated with protection from overt infection (Kundu et al., 127 2022; Swadling et al., 2022). In an unvaccinated cohort study, seronegative 128 individuals with detectable SARS-CoV-2-specific T cell responses had a lower risk of 129 subsequent infection than seronegative individuals without positive T cell responses 130 (Molodtsov et al., 2022). More recently, higher whole-blood interferon gamma (IFNy) 131 responses to SARS-CoV-2 peptides among individuals who had received at least 132 one vaccine dose were associated with a lower risk of breakthrough infection over 133 the subsequent 6-month period (Scurr et al., 2022). There are also indications that 134 the combination of cellular and humoral responses may be important in protecting 135 against Delta and Omicron breakthrough infection. The combination of high NAb titre 136 and high S1-specific IFNy responses is associated with protection against 137 breakthrough (Almendro-Vázquez et al., 2022). Also, 'high responders' to 138 vaccination, characterised by high antibody, enriched CD4+ and CD8+ central 139 memory 1, and durable CD8+ T cell responses, are more protected against 140 symptomatic breakthrough compared to 'low responders', characterised by low 141 antibody responses and more prevalent T effector memory 2 responses (Brasu et 142 al., 2022). Although these data indicate an important role for T cells, it is still unclear 143 to what extent T cell protection is mediated by CD4+ versus CD8+ T cells, as in 144 many studies only total T cell responses are investigated. However, depletion of 145 vaccine-induced CD8+ T cells in rhesus macagues and subsequent challenge 146 demonstrated that CD8+ T cells contribute to vaccine protection against SARS-CoV-147 2 replication in this model (Liu et al., 2022). Therefore, further research is needed to 148 define possible T cell CoP against SARS-CoV-2 infection, in particular the 149 contributions of CD4+ and CD8+ T cells to protection in humans.

Large-scale prospective studies with recruitment and sampling of individuals prior to
breakthrough give opportunity to better understand possible T cell CoP against
SARS-CoV-2 (Kent et al., 2022). The Protective Immunity from T Cells in Healthcare
workers (PITCH) consortium is a prospective longitudinal cohort study of cellular
immune responses to vaccination and infection in healthcare workers (HCWs) in the
UK (http://www.pitch-study.org/), aligned with the wider SARS-CoV-2 immunity &

156 reinfection evaluation (SIREN) study (Hall et al., 2022; Hall et al., 2021a; Hall et al., 157 2021b). The PITCH cohort demonstrated that an extended interval between first and 158 second dose of the BNT162b2 vaccine was associated with higher NAb and anti-S 159 IgG binding titre and lower S-specific T cell response magnitude but higher 160 interleukin-2 (IL-2) production compared to a shorter interval (Payne et al., 2021), 161 findings which were also demonstrated in a separate study of older adults (Parry et 162 al., 2022). The PITCH cohort includes individuals studied from April 2020 onwards, 163 with data from pre-vaccination through to after the fourth vaccine dose, allowing 164 sampling of well-characterised participants who subsequently experienced infection. 165 The first vaccine breakthrough case in a PITCH participant was reported on the 10<sup>th</sup> 166 June 2021, at which time, Delta was the predominant variant circulating in the UK 167 (UK Health Security Agency, 2021). A further 35 reports of vaccine breakthrough occurred in the cohort before the first Omicron cases were reported in the UK on 27th 168 169 November 2021 (Department of Health and Social Care, 2021). This offers an 170 opportunity to use samples stored from before breakthrough infection to investigate 171 CoP against infection after vaccination.

172 In the current study, we conducted a case-control study within the PITCH framework, 173 using cases who reported infection during the Delta-dominant era in the UK, and 174 controls who did not experience vaccine breakthrough during this time. Cellular and 175 humoral immunity at the timepoint 28 days after the second vaccine dose (V2+28) 176 was studied using an unmatched overall design in order to investigate whether peak 177 post-vaccination responses are associated with subsequent breakthrough infection, 178 irrespective of factors which may influence the level of response. A subset of cases 179 and matched controls were selected for more detailed analysis of cellular immunity. 180 We observed lower S- and RBD-specific IgG binding titre and lower S1- and S2-181 specific T cell responses by IFNy ELISpot assay in cases compared with controls at 182 V2+28. Using intracellular cytokine staining (ICS), we observed lower CD4+ and 183 CD8+ IFNy and tumour necrosis factor (TNF) responses to Delta peptides among 184 cases compared with matched controls.

#### 185 **RESULTS**

#### 186 Breakthrough infections during the Delta predominant era in the UK

Between 10<sup>th</sup> June and 27<sup>th</sup> November 2021, there were 36 self-reports of vaccine 187 breakthrough (positive polymerase chain reaction (PCR) or lateral flow device (LFD) 188 189 test for SARS-CoV-2 >14 days after second vaccine dose and <7 days after third 190 vaccine dose) in the PITCH cohort. These participants had been vaccinated with two doses of SARS-CoV-2 vaccine between 6<sup>th</sup> January and 17<sup>th</sup> July 2021. 26 (72.2%) 191 192 participants received BNT162b2 (Pfizer/BioNTech) and 10 (27.8%) received 193 AZD1222 (Oxford/AstraZeneca) (Table 1). The median age of vaccine breakthrough 194 cases was 43 (interguartile range [IQR] 31.5-49; range 22-72), 30 (83.3%) cases 195 were female, and the majority (93.3%) of cases were of white ethnicity, reflecting the 196 demographics of the underlying SIREN and PITCH study cohorts (Hall et al., 2021b; 197 Payne et al., 2021). The median time between second vaccine dose and positive 198 PCR or LFD test was 156 days (IQR 123.8-180.5; range 48-253).

# 199 Vaccine breakthrough is more common in individuals without history of previous200 infection

201 As expected, previous SARS-CoV-2 infection contributed to protection against further infection. Comparison of demographic characteristics of all breakthrough 202 203 infection cases (n=36) with controls, defined as eligible individuals in PITCH who did not report a positive PCR or LFD by, and were still enrolled at, the 27<sup>th</sup> November 204 205 2021 or their third vaccine dose (n=378), showed that the odds of vaccine 206 breakthrough was higher among those previously infection-naïve compared to those 207 previously infected with SARS-CoV-2 before vaccination (p=0.0009, Table 1, 208 Supplementary Figure S1). No significant association was found between odds of 209 vaccine breakthrough infection and age, sex, body mass index (BMI), ethnicity or 210 vaccine type. All cases sampled at V2+28 (n=32) were then selected for a case-211 control study with controls (n=247) being those who had been sampled at the V2+28 212 timepoint and who did not report vaccine breakthrough or show evidence of anti-

213 nucleocapsid (N) IgG seroconversion during the period of interest (Figure 1A).

#### 214 Cases have lower humoral and cellular responses than controls at V2+28

Comparing all cases with a V2+28 sample to all available controls, cases had lower anti-S (p=0.001), -RBD (p=0.003) and -N (p=0.002) IgG binding titre compared with controls (Figure 1B, C). In a subset of cases (n=21) and controls (n=41), NAb titre against ancestral and Delta variants was measured (Figure 1D). No difference in median NAb titre against ancestral variant was detected between cases and controls, although the sample size was small. There was a trend for lower median

NAb titre against the Delta variant among cases compared to controls (p=0.071).
Both cases and controls displayed a reduction in NAb titre to Delta compared to

- ancestral virus (both p<0.001). Cases also demonstrated lower ancestral S1-
- 224 (p=0.016), S2- (p=0.028) and total S- (p=0.014) specific IFNγ ELISpot responses
- compared to controls at the V2+28 timepoint (Figure 1E). Previous infection was a
- 226 strong determinant of both IgG and IFNγ responses (Supplementary Figure S2 A-G).
- 227 In a subset of individuals where cell availability permitted, IFNγ responses to peptide
- pools representing Delta S1 and S2 were assessed (Supplementary Figure S2 H-J).
- However, no difference was detected in responses between cases and controls,
- 230 possibly due to the small sample size in this analysis.

231 There was weak correlation between individual anti-S IgG titre and total S IFNy 232 responses (Figure 1F). To investigate the combined effect of antibody and cellular 233 responses on the risk of vaccine breakthrough, individuals were categorised as 234 having 'High' or 'Low' anti-S IgG and S-specific IFNy responses on the basis of 235 whether the response was above or below the median, such that individuals were 236 divided into four categories (Figure 1G). The proportion of individuals experiencing 237 vaccine breakthrough was significantly different between categories (Fisher's exact 238 test, p=0.003). The proportion of those experiencing vaccine breakthrough was 239 lowest among those with High IgG and High IFNy responses, significantly lower than 240 those with Low IgG and Low IFNy responses (pairwise Fisher's exact test, adjusted 241 p=0.005). Those with either High IgG and Low IFNy responses or Low IgG and High 242 IFNy responses had intermediate risk of breakthrough, although there was a trend 243 for a difference between those with Low IgG and High IFNy responses and those 244 with High IgG and High IFNy responses (adjusted p=0.067), highlighting the 245 importance of the IgG response.

- 246 Cases have lower S-specific T cell responses to Delta peptides compared to controls247 at V2+28
- 248 In a subset of cases and matched controls, all of whom were SARS-CoV-2 infection-249 naïve at vaccination, further analysis of cellular CoP was undertaken. Ancestral and 250 Delta S-specific memory B cell frequency was compared in a subset of cases (n=10) 251 and matched controls (n=11) where peripheral blood mononuclear cell (PBMC) 252 samples were available (Figure 2A, B). There was a trend for lower Delta S-specific 253 memory B cell frequency among cases compared to controls (p=0.088). However, 254 there was high variation among controls and an outlier among cases, meaning that 255 these data do not allow a conclusion to be drawn.
- 256 CD4+ and CD8+ T cell responses were further investigated by intracellular cytokine
- staining (ICS) in a subset of cases and matched controls where PBMC were
- available (n=12 per group). For CD4+ responses, there was a trend for lower
- 259 frequency of IFNy and TNF expressing cells in cases compared with controls, for

260 both ancestral and Delta S peptide pools (Figure 2C). This difference was significant for TNF in response to ancestral S (p=0.004), and IFNy (p=0.010) and TNF 261 262 (p=0.030) in response to Delta S peptides. There was high variability in frequency of 263 IL-2 expressing CD4+ T cells among cases and controls, with no difference detected 264 in median frequency between groups. Across CD8+ T cell responses, there was a 265 similar pattern, with a difference detected in frequency of IFNy (p=0.034) and TNF 266 (p=0.013) expressing cells in response to Delta S peptides (Figure 2D). This 267 difference appeared to be driven by a reduced response among cases to Delta 268 peptides compared to ancestral peptides, which was not present in controls. CD8+ 269 IL-2 responses appeared to be slightly higher in cases compared to controls in 270 response to ancestral S (Figure 2D, p=0.046). However, overall CD8+ IL-2 271 responses were very low and this trend appeared to be driven by one outlier with 272 very high CD8+ responses across all cytokines.

273 Across IFNy and TNF responses, on average over half of the response was 274 contributed by CD4+ T cells, however there was substantial variation between 275 individuals (Supplementary Figure S3A, B). A higher proportion of the TNF response 276 to Delta peptide pools was contributed by CD4+ T cells among cases compared to 277 controls (p=0.028). CD4+ T cells contributed almost all of the IL-2 response to 278 ancestral and Delta S peptide pools across the majority of cases and controls 279 (Supplementary Figure S3C). Polyfunctionality analysis indicated that cases had a 280 lower frequency of TNF/IFNy+ double positive CD4+ and CD8+ T cells in response 281 to Delta peptides compared with controls (Supplementary Figure S3E, G). There was 282 also a trend for lower frequency of TNF+ single positive CD4+ and CD8+ T cells 283 among cases compared to controls (Supplementary Figure S3 D-G).

#### 284 **DISCUSSION**

285 This study examines potential CoP against SARS-CoV-2 breakthrough infection after 286 two vaccine doses during the Delta-predominant era in the UK. Breakthrough 287 infection was less likely in those with previous SARS-CoV-2 infection compared with 288 those previously infection-naïve, consistent with other reports (Dhumal et al., 2022; 289 Torres et al., 2022a). Cases showed lower anti-S and -RBD IgG binding titre, as well 290 as lower S1- and S2-specific IFNy T cell responses by ELISpot assay, compared 291 with controls. In further analysis by ICS, lower CD4+ and CD8+ IFNy and TNF 292 responses to Delta S peptide pools were found among cases compared to controls. 293 Our detailed look at spike-specific T cell function with sensitive assays provides 294 further evidence of T cell CoP to add to established serological CoP from large 295 studies of humoral function.

296 Our finding that anti-S and -RBD IgG binding titres differ between those who go on to 297 experience breakthrough and those who do not experience overt infection is 298 consistent with a number of other reports which previously demonstrated an 299 association between these parameters and risk of breakthrough infection (Aldridge et 300 al., 2022; Feng et al., 2021; Wei et al., 2022). The SIREN study is also well placed to 301 look at serological CoP against reinfection in a large cohort of HCWs which includes 302 several cases and controls from this study. SIREN recently reported that anti-S 303 antibody levels and NAb titres correlated with protection against reinfection during 304 the Alpha wave, prior to vaccination (Atti et al., 2022).

305 In this study, vaccine breakthrough was associated with lower IFNy T cell responses 306 by ELISpot, and lower CD4+ and CD8+ IFNy and TNF responses to Delta peptides 307 in ICS, even using a modest sample size. There are increasing reports indicating an 308 important role for T cell CoP alongside serological CoP (Almendro-Vázquez et al., 309 2022; Molodtsov et al., 2022; Scurr et al., 2022). Our findings using the IFNy ELISpot 310 assay help to validate these reports. Our more detailed findings using ICS support a 311 role for both CD4+ and CD8+ T cells in protecting against susceptibility to overt 312 infection with the Delta variant. The apparent drop in CD8+ IFNy and TNF responses 313 to Delta peptides compared with ancestral peptides among cases was particularly 314 striking and suggests a role for variant-specific CD8+ T cells in protection against 315 infection with the Delta variant. Previous studies in a rhesus macague model support 316 a role for CD8+ T cell responses in protection against re-challenge in the context of 317 waning antibody levels (McMahan et al., 2021), and a direct role in vaccine-induced 318 protection against SARS-CoV-2 replication (Liu et al., 2022). In addition, infection-319 naïve vaccinees with high antibody responses have enriched CD4+ and CD8+ 320 central memory 1 cell responses and durable CD8+ T cell responses to ancestral 321 and VOC S peptides compared to those with low antibody responses, and are 322 protected against symptomatic breakthrough infection with Delta or Omicron (Brasu 323 et al., 2022). Virus-specific CD8+ T cells are associated with protection against

324 infection with other viral pathogens. For example, in the context of influenza A virus 325 (IAV) epidemics, each fold increase in pre-existing H3N2- or seasonal H1N1-specific 326 CD8+ T cell response is associated with reduced odds of infection with H3N2 or 327 pandemic H1N1 IAV respectively (Tsang et al., 2022). IFNy+IL2- CD8+ T cells 328 specific for conserved IAV core protein epitopes are also associated with protection 329 against symptomatic disease caused by pandemic H1N1 IAV (Sridhar et al., 2013). 330 Several human studies investigating immune responses around the time of SARS-331 CoV-2 breakthrough infection have not identified differences in T cell responses 332 between cases and controls, but have identified differences in terms of NAb titre 333 (Park et al., 2022; Rovida et al., 2021) and memory B cell responses (Tay et al., 334 2022). The difference in results between these studies and our study may be due to 335 different timing of sampling and/or SARS-CoV-2 variant. 336 Our study focused on the Delta wave of infections in the UK, during a time at which 337 the study participants had received two vaccine doses. However, the Delta variant 338 has been largely displaced by Omicron in the UK and globally, and in the UK a third 339 SARS-CoV-2 vaccine dose has been recommended to all adults (UK Health Security 340 Agency, 2022) with further doses for those at increased risk and HCWs. The

generalisability of the findings of this study to Omicron breakthroughs occurring after
 two or three vaccine doses needs further evaluation. Studies of CoP against

- 343 Omicron have reported mixed results. A study investigating breakthrough after two
- 344 vaccine doses found that there was no difference in anti-RBD titre between cases
- 345 who subsequently experienced Omicron breakthrough and controls (Smoot et al.,
- 346 2022). Other studies did not identify differences in anti-S IgG titre (Stærke et al.,
- 347 2022), anti-RBD IgG titre, Omicron NAb titre or T cell IFNγ responses (Torres et al.,
- 348 2022b) after a third vaccine dose between those who subsequently experienced
- 349 Omicron breakthrough and those who did not. However, others have reported that
- low anti-S Ab titre and weak neutralisation post-third dose is associated with higher risk of breakthrough (Mohlendick et al., 2022). In the peri-infection period, low pre-
- risk of breakthrough (Mohlendick et al., 2022). In the peri-infection period, low pre-
- infection anti-S IgG titre is associated with breakthrough (Nunes et al., 2022);
- however, it has also been shown that Omicron breakthrough can occur in those with high NAb titres (Roeder et al., 2022).

### 355 Limitations

356 Important limitations are as follows. (i) The sample size for cases is relatively small, 357 despite follow up of a large number of individuals in the overall PITCH consortium, 358 because breakthrough infection during this time (pre-Omicron) was still relatively 359 rare. We used the maximum sample size available for this case-control study for 360 each assay type, however, the small number of cases means there was inadequate 361 power to conduct a fully adjusted analysis of the effect of humoral and cellular 362 responses on odds of vaccine breakthrough using logistic regression. This means 363 there may be some confounding in our analysis, for example, due to previous

364 infection. However, non-mechanistic CoP are still useful. There are unfortunately no 365 further stored PBMC samples available for analysis. (ii) Sequence information was 366 not available so we were unable to confirm whether these breakthrough infections 367 were attributable to the Delta variant. However, during the period in which the 368 infections occurred, Delta was the predominant variant in the UK, causing  $\geq$ 89.9% of 369 genotyped infections throughout this time. This approach using the timing of infection 370 to indicate which variant is likely the cause of infection is in line with approaches 371 used in other studies (Collie et al., 2022). (iii) Our study was not designed to explore 372 specific co-morbidities, particularly immunosuppression, as risk factors for 373 breakthrough infection (Green et al., 2022; Selvavinayagam et al., 2022). This is 374 addressed in the subsequent VIBRANT study (https://vibrant-research-study.org/). 375 (iv) All observational studies carry the risk of bias. Adherence to LFD and PCR 376 testing recommendations was not monitored within PITCH, thus there may be some 377 mis-classification of controls. Although serology from later follow up points was used 378 to confirm as far as possible that controls were not infected during the period of 379 interest, up to 60% of vaccinated individuals may not undergo anti-N seroconversion 380 upon infection (Follmann et al., 2022). It is likely there were differences in exposure 381 to SARS-CoV-2 between individuals dependent on their exact HCW role, for 382 example, seeing more than one COVID-19 patient per day has previously been 383 associated with a higher risk of infection among HCWs (Feng et al., 2021); however, 384 this information was not available for us to take in to account in analysis. (v) We did 385 not investigate mucosal immunity in this study, as mucosal samples were not 386 obtained from PITCH participants at that time. Mucosal immune responses do not 387 necessarily correlate with responses in the peripheral circulation (Lim et al., 2022), 388 and may play an important role in protection against SARS-CoV-2 infection, 389 particularly in individuals with hybrid immunity (Russell and Mestecky, 2022). 390 Ongoing PITCH research now incorporates measurement of mucosal immunity. 391 Nonetheless, this study has several strengths, primarily that the PITCH cohort is very 392 well characterised, and the prospective nature of the study allowed investigation at a 393 pre-specified timepoint reflecting peak vaccine responses, prior to infection.

394 Questions remain regarding the mechanism of action of these putative T cell CoP. 395 CD8+ T cells may contribute to control of replication after infection, as demonstrated 396 in a rhesus macaque model (Liu et al., 2022). CD4+ T cells are important for 397 providing T cell help to support CD8+ T cells and for generation of Ab responses. 398 There may also be a role for HLA type and which epitopes are immunodominant in 399 different individuals. For example, it has been shown that there is an association 400 between the HLA-DQB1\*06 allele and higher anti-RBD IgG titre after vaccination 401 with AZD1222, and that this may play a role in protection from breakthrough infection 402 with ancestral and Alpha strains (Mentzer et al., 2022).

403 Overall, our study supports a role for T cell responses alongside antibody responses404 in protection against detectable infection during the period after double vaccination,

- 405 over which antibody responses have been shown to wane (Levin et al., 2021; Moore
- 406 et al., 2022; Naaber et al., 2021). Moreover, our results suggest a potential role for
- 407 variant-specific CD8+ T cell responses. Development of sensitive, quantitative T cell
- 408 assays that can be used at scale in large cohorts in a range of settings will allow
- 409 further integrated study of humoral and cellular adaptive immunity and inform
- 410 vaccine surveillance and effectiveness monitoring.

#### 411 METHODS

#### 412 Study design and sample collection

413 The PITCH consortium has been described previously (Angyal et al., 2022; Moore et 414 al., 2022; Payne et al., 2021). Briefly, participants in this prospective, observational, 415 cohort study were recruited from five university hospitals in England (Birmingham, 416 Liverpool, Newcastle, Oxford and Sheffield). Recruitment of consenting individuals 417 was by word of mouth, hospital e-mail communications and from hospital-based staff 418 screening programmes for SARS-CoV-2, including HCWs enrolled in the national 419 SIREN study at three sites (Liverpool, Newcastle and Sheffield). Eligible participants 420 were adults aged 18 or over, and currently working as HCWs, including allied 421 support and laboratory staff, or were volunteers linked to the hospital. Individuals 422 were defined as SARS-CoV-2 naive or previously-infected based on documented 423 PCR and/or serology results from local NHS trusts, or the Meso Scale Discovery 424 (MSD) assay S and N antibody results if these data were not available locally, as 425 described previously (Payne et al., 2021).

426 PITCH is a sub-study of the SIREN study, which was approved by the Berkshire 427 Research Ethics Committee, Health Research 250 Authority (IRAS ID 284460, REC 428 reference 20/SC/0230), with PITCH recognised as a sub-study on 2 December 2020. 429 SIREN is registered with ISRCTN (Trial ID: 252 ISRCTN11041050). Some 430 participants were recruited under aligned study protocols. In Birmingham participants 431 were recruited under the "Determining the immune response to SARS-CoV-2 432 infection in convalescent health care workers" (COCO) study (IRAS ID: 282525). In 433 Liverpool some participants were recruited under the "Human immune responses to 434 acute virus infections" Study (16/NW/0170), approved by North West - Liverpool 435 Central Research Ethics Committee on 8 March 2016, and amended on 14th 436 September 2020 and 4th May 2021. In Oxford, participants were recruited under the 437 GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at 438 Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016, 439 which has been amended for this purpose on 8 June 2020. In Sheffield, participants 440 were recruited under the Observational Biobanking study STHObs (18/YH/0441), 441 which was amended for this study on 10 September 2020. The study was conducted 442 in compliance with all relevant ethical regulations for work with human participants, 443 and according to the principles of the Declaration of Helsinki (2008) and the 444 International Conference on Harmonization (ICH) Good Clinical Practice (GCP) 445 guidelines. Written informed consent was obtained for all participants enrolled in the 446 study.

The current study is nested within PITCH. A vaccine breakthrough case was defined
as a self-reported positive PCR or LFD test for SARS-CoV-2 >14 days after second
vaccine dose and <7 days after the third vaccine dose. The period of interest for</li>

450 cases was when Delta was the predominant circulating SARS-CoV-2 variant in the UK. defined here as 6<sup>th</sup> June to 27<sup>th</sup> November 2021, with 27<sup>th</sup> November taken as 451 452 the cut-off date as this was the date of the first reported cases of SARS-CoV-2 453 Omicron variant in the UK (Department of Health and Social Care, 2021). 454 Throughout this period ≥89.9% of genotyped infections across England were 455 attributable to the Delta variant (UK Health Security Agency, 2021). During this 456 period all UK HCWs were requested to undertake twice-weekly asymptomatic testing 457 for SARS-CoV-2 using self-swab LFDs which were provided free of charge by 458 workplaces, pharmacies and by postal delivery from the government website. 459 Symptomatic PCR testing was readily available at this time free of charge from 460 hospital trusts and UK community testing programmes. Adherence to this testing 461 was not measured within PITCH, however, PITCH participants are asked about 462 SARS-CoV-2 infections at every clinic visit.

463 The current study has a case-control design (Supplementary Figure S1). Eligibility criteria were enrolment in PITCH by 30<sup>th</sup> June 2021, and being double vaccinated by 464 31<sup>st</sup> July 2021. For correlates analysis, all those meeting the criteria of a vaccine 465 466 breakthrough case and who had been sampled at the V2+28 timepoint were 467 included. Controls were those who had been sampled at the V2+28 timepoint and did not report a positive PCR or LFD by 27<sup>th</sup> November 2021 or 7 days after the third 468 469 vaccine dose (V3+7), whichever was earlier, and who did not show detectable N 470 seroconversion (defined as anti-N IgG titre over the positivity threshold previously 471 defined using pre-pandemic samples (Angyal et al., 2022), and at least double the 472 individual's baseline value) in available follow-up data during this time 473 (Supplementary Table S1, S2).

A subset of cases was selected on the basis of sample availability for further
analysis using ICS and memory B cell FluoroSpot. Controls were matched with these
cases for each assay, with matching based on age, sex, previous infection status at
enrolment, vaccine manufacturer and dose interval (Supplementary Table S3).
Cases in this matched analysis had been enrolled at multiple sites, whereas controls
had all been enrolled at the Oxford site. All experiments for this subset analysis were

- 480 conducted at the Oxford site.
- 481 Participants were sampled for the current study between 4<sup>th</sup> January 2021 and 13<sup>th</sup>

482 August 2021, approximately 28 days after their second vaccine dose (median 28

- 483 days, IQR 26-33 days). PBMC, plasma and serum were separated and
- 484 cryopreserved. The majority of participants had been investigated for previous
- reports of the PITCH cohort (Angyal et al., 2022; Moore et al., 2022; Payne et al.,

486 2021; Skelly et al., 2021).

#### 487 Demographic analysis

488 Demographic characteristics of vaccine breakthrough cases compared to the PITCH 489 cohort were initially analysed by univariable logistic regression to estimate the crude 490 odds ratio for vaccine breakthrough for each variable. A likelihood ratio test was 491 conducted with the null hypothesis of no association between vaccine breakthrough 492 and each variable. An adjusted model was derived by backwards stepwise 493 regression, with age and sex included as a priori confounders. Variables were 494 removed from the model sequentially, beginning with those with the least effect in 495 univariable regression. A likelihood ratio test was conducted after each removal, and 496 only those variables with evidence of association with vaccine breakthrough (p<0.05) 497 were retained in the model. Analysis was performed using R version 4.1.2 (The R 498 Foundation for Statistical Computing, Vienna, Austria, 2021. URL https://www.R-499 project.org/). Confidence intervals were derived using the confint package.

#### 500 T cell IFNy ELISpot assay

501 IFNy ELISpot assays were performed using the Human IFNy ELISpot Basic kit 502 (Mabtech 3420-2A), according to the PITCH ELISpot Standard Operating Procedure 503 as previously published (Angyal et al., 2022). Cryopreserved PBMC were thawed in 504 R10 media (RPMI 1640 with 10% (v/v) Fetal Bovine Serum, 2mM L-Glutamine and 505 1mM Penicillin/Streptomycin (all Sigma)) and rested for 3-6 hours in a humidified 506 incubator at 37°C, 5% CO<sub>2</sub>. MultiScreen-IP filter plates (Millipore) were coated with 507 10µg/ml capture antibody (clone 1-D1K, Mabtech) for 3-8 hours and blocked with 508 R10 or Rab10 (RPMI 1640 with 2mM L-Glutamine and 1mM Penicillin/Streptomycin 509 supplemented with 10% (v/v) Human AB Serum (Sigma)) for 1-8 hours at room 510 temperature (RT). PBMC were resuspended in R10 or Rab10, plated in triplicate at 511 2x10<sup>5</sup> cells/well and stimulated as follows. PBMC were stimulated with overlapping 512 peptide pools (18-mers with 10 amino acid overlap, Mimotopes) spanning the S or 513 membrane (M) and N SARS-CoV-2 proteins at a final concentration of 2µg/ml for 16-514 18 hours in a humidified incubator at  $37^{\circ}$ C, 5% CO<sub>2</sub>. For selected individuals, pools 515 spanning S protein of the Delta variant were included. Pools consisting of CMV, EBV 516 and influenza peptides at a final concentration of 2µg/ml (CEF; Proimmune) and 517 concanavalin A or phytohemagglutinin L (PHA-L, Sigma) were used as positive 518 controls. DMSO was used as the negative control at an equivalent concentration to 519 the peptides. After the incubation period and all subsequent steps plates were 520 washed with PBS supplemented with 0.05% (v/v) Tween20 (Sigma). Detection 521 antibody (clone 7-B6-1, Mabtech) was added and incubated for 2-4 hours at RT. 522 Plates were washed and streptavidin-ALP (Mabtech) added for 1-2 hours at RT, 523 before washing again and addition of 1-step NBT/BCIP substrate solution (Thermo 524 Scientific) for 5-7 minutes at RT. Colour development was stopped by washing with 525 tap water. Air-dried plates were scanned and analysed with the AID Classic ELISpot 526 reader (software version 8.0, Autoimmune Diagnostika GmbH, Germany) or 527 ImmunoSpot® S6 Alfa Analyser (Cellular Technology Limited LLC, Germany). 528 Antigen-specific responses were calculated by subtracting the mean number of spots

- 529 in the DMSO wells from the test wells and expressed as spot-forming units
- 530 (SFU)/10<sup>6</sup> PBMC. Samples with a mean spot value >50 in the DMSO wells were
- 531 excluded from analysis.

#### 532 MSD IgG binding assay

533 IgG responses to SARS-CoV-2, SARS-CoV-1, MERS-CoV and seasonal 534 coronaviruses were measured using a multiplexed MSD immunoassay (The V-PLEX 535 COVID-19 Coronavirus Panel 3 (IgG) Kit (cat. no. K15399U) from Meso Scale 536 Discovery, Rockville, MD USA), as reported previously (Moore et al., 2022; Payne et 537 al., 2021). A MULTI-SPOT® 96-well, 10 spot plate was coated with three SARS 538 CoV-2 antigens (S, RBD, N), SARS-CoV-1 and MERS-CoV spike trimers, spike 539 proteins from seasonal human coronaviruses, HCoV-OC43, HCoV-HKU1, HCoV-540 229E and HCoV-NL63, and bovine serum albumin (negative control). Antigens were 541 spotted at 200–400 µg/mL (MSD® Coronavirus Plate 3). Multiplex MSD assays were 542 performed as per the manufacturer's instructions. To measure IgG antibodies, 96-543 well plates were blocked with MSD Blocker A for 30 minutes. Following washing with 544 washing buffer, serum or plasma samples diluted 1:1,000-30,000 in diluent buffer, 545 MSD standard and undiluted internal MSD controls, were added to the wells. After 2-546 hour incubation and washing, detection antibody (MSD SULFO-TAG<sup>™</sup> anti-human 547 IgG antibody, 1/200) was added. Following washing, MSD GOLD<sup>™</sup> read buffer B 548 was added and plates were read using a MESO® SECTOR S 600 reader. The 549 standard curve was established by fitting the signals from the reference standard 550 using a 4-parameter logistic model. Concentrations of samples were determined 551 from the electrochemiluminescence signals by back-fitting to the standard curve and 552 multiplying by the dilution factor. Concentrations are expressed in Arbitrary Units/ml 553 (AU/ml). Thresholds were previously determined for each SARS-CoV-2 antigen 554 based on the mean concentrations measured in 103 pre-pandemic sera + 3 555 Standard Deviations (Angyal et al., 2022). Thresholds were: S, 1160 AU/ml; RBD, 556 1169 AU/ml; and N, 3874 AU/ml.

#### 557 Memory B cell IgG FluoroSpot assay

558 In a subset of cases and matched controls for which PBMC were available, B cell 559 memory responses were characterised by IgG FluoroSpot assay, according to 560 methods previously reported (Moore et al., 2022). Cryopreserved PBMC were 561 thawed and rested for 4-6 hours in R10 media, then cultured in R10 supplemented 562 with 2mM Sodium Pyruvate, 2mM MEM Non-Essential Amino Acids, 200nM 2-563 Mercaptoethanol (all Life Technologies), 1µg/ml R848 and 10ng/ml IL-2 (Mabtech 564 Human memory B cell stimpack) for 68-72 hours in a humidified incubator at 37°C, 565 5% CO<sub>2</sub>, for polyclonal stimulation. Using the Human IgA/IgG FluoroSpotFLEX kit (Mabtech), stimulated PBMC were then added at 2x10<sup>5</sup> cells/well to FluoroSpot 566 567 plates coated with 10µg/ml ancestral and Delta SARS-CoV-2 S glycoprotein, PBS

568 (negative control) or capture mAbs (positive control). Plates were incubated for 18

- hours in a humidified incubator at 37°C, 5% CO<sub>2</sub> and developed according to the
- 570 manufacturer's instructions (Mabtech). Analysis was carried out with AID ELISpot
- 571 software 8.0 (Autoimmun Diagnostika). Samples were tested in duplicate, or
- 572 triplicate where cell counts permitted. Antigen-specific responses were calculated by
- subtracting the mean number of spots in the PBS wells from the test wells and
- 574 expressed as antibody-secreting cells (ASC)/10<sup>6</sup> PBMC.

#### 575 Intracellular cytokine staining assay

576 In a subset of cases and matched controls for which PBMC were available, T cell 577 responses were characterised further using ICS after stimulation with overlapping 578 SARS-CoV-2 peptide pools, according to methods reported previously (Moore et al., 579 2022). Cryopreserved PBMC were thawed and rested in R10 media for 4-6 hours, then plated at 1x10<sup>6</sup> cells/well in a 96-well U-bottom plate together with co-580 581 stimulatory molecules anti-CD28 and anti-CD49d (both BD) at 1µg/ml final 582 concentration. Peptide pools spanning ancestral and Delta S proteins were added at 583 2µg/ml final concentration for each peptide pool. DMSO (Sigma) was used as the 584 negative control at the equivalent concentration to the peptides. As a positive control, 585 cells were stimulated with 1x cell activation cocktail containing phorbol-12-myristate 586 13-acetate (PMA) at 81µM and ionomycin at 1.3µM final concentration (Biolegend). 587 Cells were then incubated in a humidified incubator at 37°C, 5% CO<sub>2</sub> for 1 hour 588 before incubating for a further 15 hours in the presence of 5µg/ml Brefeldin A 589 (Biolegend). Flow cytometry staining was then performed as follows. Cell staining 590 buffer (Biolegend) was used for staining and washing before fixation, with 1x 591 Perm/Wash buffer (BD) used after fixation. At the end of the culture period, PBMC 592 were washed once and subsequently stained with near-infrared fixable live/dead 593 stain (Invitrogen), fluorochrome-conjugated primary human-specific antibodies 594 against CD4, CD8 and CD14 (all Biolegend) and human Fc blocking reagent 595 (Miltenyi Biotec) for 20 minutes at 4°C in the dark. PBMC were washed and then 596 fixed and permeabilised in Cytofix/Cytoperm buffer (BD) for 20 minutes at 4°C in the 597 dark. PBMC were then washed followed by staining with primary human-specific 598 antibodies against CD3, IFNy, TNF (all Biolegend), IL-2 (eBioscience) and human Fc 599 blocking reagent for 20 minutes at 4°C in the dark. PBMC were washed, 600 resuspended in cell staining buffer, and stored at 4°C for up to 6 hours until 601 acquisition. Samples were acquired on a MACSQuant analyser 10 and X (Miltenyi 602 Biotec) and analysis was performed using FlowJo software version 10.8.1 (BD 603 Biosciences). Example gating strategy is shown in Supplementary Figure S4. Details 604 of antibodies used are listed in Supplementary Table S4.

#### 605 High-throughput live virus microneutralisation assay

606 In a subset of cases and controls, high-throughput live virus microneutralisation 607 assays were performed as described previously (Faulkner et al., 2021; Wall et al., 608 2021). Briefly, Vero E6 cells (Institute Pasteur) (Rihn et al., 2021) at 90-100% 609 confluency in 384-well format were first titrated with varying MOIs of each SARS-610 CoV-2 variant and varying concentrations of a control monoclonal nanobody in order 611 to normalise for possible replicative differences between variants and select 612 conditions equivalent to wild-type virus. Following this calibration, cells were infected 613 in the presence of serial dilutions of patient serum samples. 24 hrs after infection, 614 cells were fixed with 4% final Formaldehyde, permeabilised with 0.2% TritonX-100, 615 3% BSA in PBS (v/v), and stained for SARS-CoV-2 N protein using Biotin-labelled-616 CR3009 antibody produced in-house in conjunction with Alexa488-Streptavidin 617 (Invitrogen S32354) and cellular DNA using DAPI (van den Brink et al., 2005). 618 Whole-well imaging at 5x was carried out using an Opera Phenix (Perkin Elmer) and 619 fluorescent areas and intensity calculated using the Phenix-associated software 620 Harmony (Perkin Elmer). Inhibition was estimated from the measured area of 621 infected cells/total area occupied by all cells. The inhibitory profile of each serum 622 sample was estimated by fitting a 4-parameter dose response curve executed in 623 SciPy. Neutralising antibody titres are reported as the fold-dilution of serum required 624 to inhibit 50% of viral replication (IC50), and are further annotated if they lie above 625 the quantitative (complete inhibition) range (titre >2560), below the quantitative range 626 (<40) but still within the qualitative range (i.e. partial inhibition is observed but a 627 dose-response curve cannot be fit because it does not sufficiently span the IC50), or 628 if they show no inhibition at all. For plotting, complete, weak and no inhibition were 629 assigned 5120, 10 and 5 respectively. Details of viruses used in the study are listed 630 in Supplementary Table S5.

#### 631 Statistical analysis

632 Continuous variables are displayed as median and interquartile range (IQR).

633 Unpaired comparisons between two groups were analysed using the Mann-Whitney

634 U test. Paired comparisons between two groups were analysed by the Wilcoxon

635 matched-pairs signed-rank test. Comparison between four groups was carried out

636 using Fisher's exact test and post-hoc paired Fisher's exact tests adjusted with the

637 Bonferroni correction. P values are two-tailed. Statistical analyses were performed

using R version 4.1.2 (The R Foundation for Statistical Computing, Vienna, Austria,

639 2021. URL <u>https://www.R-project.org/</u>) and GraphPad Prism 9.4.0.

#### 640 **ACKNOWLEDGEMENTS**

- 641 We are grateful to all the volunteers who participated in the PITCH study. For the
- Birmingham participants, the study was carried out at the National Institute for Health
- 643 Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility. Laboratory
- 644 studies were undertaken by the Clinical Immunology Service, University of
- 645 Birmingham. We thank Prof. Wendy Barclay of Imperial College and the wider
- 646 Genotype to Phenotype consortium for the Delta strain used for the live virus
- 647 microneutralisation assay in this study.

### 648 AUTHOR CONTRIBUTIONS

- 649 Conceptualization, S.J.D, P.K, T.L, A.R, C.J.A.D, L.T, T.I.d.S, M.C, S.H, V.H;
- 650 Methodology, S.J.D, P.K, T.L, B.K, S.L, E.J.C, R.B, A.R, C.J.A.D, L.T, T.I.d.S, M.C;
- 651 Formal analysis, I.N, M.A; Investigation, I.N, M.A, S.L, P.A, M.Y.W, E.J.C, L.S, S.D,
- 652 M.P, T.A.H.N, R.P.P, E.B, C.J.A.D, A.R, R.B; Resources, A.B, A.D.O; Data Curation,
- 653 S.C.M, A.S.D; Writing Original Draft, I.N; Writing Review & Editing, S.J.D, P.K,
- T.L, T.I.d.S, L.T., E.J.C, S.L, M.A; Visualization, I.N; Supervision, S.J.D, P.K, T.L,
- B.K, M.C, T.I.d.S, L.T, A.T; Project Administration, A.S.D; Funding Acquisition, P.K.,
- 656 S.J.D., L.T., T.I.d.S, C.J.A.D., A.R., S.H., V.H.

### 657 FUNDING STATEMENT

This research was funded in part by the Wellcome Trust (WT109965MA,

- 659 110058/Z/15/Z, 204721/Z/16/Z, 211153/Z/18/Z, 205228/Z/16/Z, 090532/Z/09/Z,
- 660 CC2230, CC2087). This work was funded by the United Kingdom Department of
- 661 Health and Social Care as part of the PITCH (Protective Immunity from T cells to
- 662 COVID-19 in Healthcare Workers) Consortium, UKRI as part of "Investigation of
- 663 proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare
- 664 worker cohorts: SIREN consortium & PITCH Plus Pathway" (MR/W02067X/1), with
- 665 contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium
- 666 (UK-CIC), the Huo Family Foundation and The National Institute for Health Research
- 667 (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number
- 668 COV19-RECPLAS). This work was supported by the Francis Crick Institute which
- receives its core funding from Cancer Research UK (CC2230, CC2087), the UK
- 670 Medical Research Council (CC2230, CC2087), and the Wellcome Trust (CC2230,
- 671 CC2087).
- 672 S.D. is funded by an NIHR Global Research Professorship (NIHR300791). E.B. and
- 673 P.K. are NIHR Senior Investigators and P.K. is funded by WT109965MA. T.I.d.S is
- 674 funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z).
- 675 R.P.P. is funded by a Career Re-entry Fellowship (204721/Z/16/Z). C.J.A.D. is

- 676 funded by a Wellcome Clinical Research Career Development Fellowship (211153/Z/18/Z). L.T. is supported by the Wellcome Trust (205228/Z/16/Z), the 677 678 National Institute for Health Research Health Protection Research Unit (NIHR 679 HPRU) in Emerging and Zoonotic Infections (EZI) (NIHR200907) and the Centre of 680 Excellence in Infectious Diseases Research (CEIDR) and the Alder Hey Charity. The 681 HPRU-EZI at University of Liverpool is in partnership with UK Health Security 682 Agency, in collaboration with Liverpool School of Tropical Medicine and the 683 University of Oxford. M.C., S.L., and L.T. are supported by US Food and Drug 684 Administration Medical Countermeasures Initiative contract 75F40120C00085. The 685 Wellcome Centre for Human Genetics is supported by the Wellcome Trust 686 (090532/Z/09/Z). The Sheffield Teaching Hospitals Observational Study of Patients 687 with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-688 ObS) was supported by the British Heart Foundation (PG/11/116/29288). The STH-689 ObS Chief Investigator Allan Lawrie is supported by a British Heart Foundation 690 Senior Basic Science Research Fellowship (FS/18/52/33808). We gratefully 691 acknowledge financial support from the UK Department of Health via the Sheffield 692 NIHR Clinical Research Facility award to the Sheffield Teaching Hospitals 693 Foundation NHS Trust.
- The views expressed are those of the author(s) and not necessarily those of the
- NHS, the NIHR, the Department of Health and Social Care or UK Health Security
- Agency, or the US Food and Drug Administration.

#### 697 **COMPETING INTEREST STATEMENT**

698 S.D. is a Scientific Advisor to the Scottish Parliament on COVID-19 for which she

699 receives a fee. Oxford University has entered a joint COVID-19 vaccine development

700 partnership with AstraZeneca. All other authors have declared no competing

701 interests.

#### 702 REFERENCES

703 Addetia, A., Crawford, K.H.D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.L., 704 Jerome, K.R., Bloom, J.D., and Greninger, A.L. (2020). Neutralizing Antibodies Correlate 705 with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High

706 Attack Rate. Journal of Clinical Microbiology 58. 10.1128/jcm.02107-20.

707 Aldridge, R.W., Yavlinsky, A., Nguyen, V., Eyre, M.T., Shrotri, M., Navaratnam, A.M.D., 708 Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022). SARS-CoV-2 antibodies and 709 breakthrough infections in the Virus Watch cohort. Nature Communications 13.

710 10.1038/s41467-022-32265-5.

711 Almendro-Vázquez, P., Chivite-Lacaba, M., Utrero-Rico, A., González-Cuadrado, C., 712 Laguna-Goya, R., Moreno-Batanero, M., Sánchez-Paz, L., Luczkowiak, J., Labiod, N., 713 Folgueira, M.D., et al. (2022). Cellular and humoral immune responses and breakthrough

- 714 infections after three SARS-CoV-2 mRNA vaccine doses. Frontiers in Immunology 13,
- 715 981350-981350. 10.3389/fimmu.2022.981350.

716 Angyal, A., Longet, S., Moore, S., Payne, R.P., Harding, A., Tipton, T., Rongkard, P., Ali, M., 717 Hering, L.M., Meardon, N., et al. (2022). T-cell and antibody responses to first BNT162b2 718 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a 719 multicentre prospective cohort study. The Lancet Microbe 3, e21-e31. 10.1016/s2666-720 5247(21)00275-5.

721 Atti, A., Insalata, F., Carr, E.J., Otter, A.D., Castillo-Olivares, J., Wu, M., Harvey, R., Howell, 722 M., Chan, A., Lyall, J., et al. (2022). Antibody correlates of protection from SARS-CoV-2 723 reinfection prior to vaccination: A nested case-control within the SIREN study. Journal of 724 Infection 85, 545-556. 10.1016/j.jinf.2022.09.004.

725 Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., 726 Levin, E.G., Rubin, C., Indenbaum, V., et al. (2021). Covid-19 Breakthrough Infections in 727 Vaccinated Health Care Workers. New England Journal of Medicine 385, 1474-1484. 728 10.1056/nejmoa2109072.

729 Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S.A., De Intinis, C., Fesi, F., Gizzi, 730 K., Macagno, M., Montone, M., et al. (2022). Memory CD8+ T cell diversity and B cell 731 responses correlate with protection against SARS-CoV-2 following mRNA vaccination. 732 Nature Immunology 23, 1445-1456. 10.1038/s41590-022-01313-z.

733 Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E.,

- 734 Cromer, D., Scheepers, C., Amoako, D.G., et al. (2022). Omicron extensively but
- 735 incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654-656. 736
- 10.1038/s41586-021-04387-1.
- 737 Chau, N.V.V., Ngoc, N.M., Nguyet, L.A., Quang, V.M., Ny, N.T.H., Khoa, D.B., Phong, N.T.,
- 738 Toan, L.M., Hong, N.T.T., Tuyen, N.T.K., et al. (2021). An observational study of
- 739 breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in 740 Vietnam. eClinicalMedicine 41, 101143. 10.1016/j.eclinm.2021.101143.

741 Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., and Gray, G. (2022). Effectiveness of 742 BNT162b2 Vaccine against Omicron Variant in South Africa. New England Journal of 743 Medicine 386, 494-496. 10.1056/nejmc2119270.

744 Department of Health and Social Care (2021). Press Release: First UK cases of Omicron 745 variant identified. <u>https://www.gov.uk/government/news/first-uk-cases-of-omicron-variant-</u>

746 <u>identified</u>.

747 Dhumal, S., Patil, A., More, A., Kamtalwar, S., Joshi, A., Gokarn, A., Mirgh, S., Thatikonda,

P., Bhat, P., Murthy, V., et al. (2022). SARS-CoV-2 reinfection after previous infection and

- vaccine breakthrough infection through the second wave of pandemic in India: An
- observational study. International Journal of Infectious Diseases *118*, 95-103.
- 751 10.1016/j.ijid.2022.02.037.
- Earle, K.A., Ambrosino, D.M., Fiore-Gartland, A., Goldblatt, D., Gilbert, P.B., Siber, G.R.,

753 Dull, P., and Plotkin, S.A. (2021). Evidence for antibody as a protective correlate for COVID-754 19 vaccines. Vaccine *3*9, 4423-4428. 10.1016/j.vaccine.2021.05.063.

Faulkner, N., Ng, K.W., Wu, M.Y., Harvey, R., Margaritis, M., Paraskevopoulou, S.,
Houlihan, C., Hussain, S., Greco, M., Bolland, W., et al. (2021). Reduced antibody crossreactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. eLife *10*.
10.7554/elife.69317.

Feng, S., Phillips, D.J., White, T., Sayal, H., Aley, P.K., Bibi, S., Dold, C., Fuskova, M.,
Gilbert, S.C., Hirsch, I., et al. (2021). Correlates of protection against symptomatic and
asymptomatic SARS-CoV-2 infection. Nature Medicine *27*, 2032-2040. 10.1038/s41591-02101540-1.

Follmann, D., Janes, H.E., Buhule, O.D., Zhou, H., Girard, B., Marks, K., Kotloff, K.,
Desjardins, M., Corey, L., Neuzil, K.M., et al. (2022). Antinucleocapsid Antibodies After
SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med *175*, 1258-1265.
10.7326/M22-1300.

Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,
Österborg, A., Bergman, P., et al. (2022). Ancestral SARS-CoV-2-specific T cells crossrecognize the Omicron variant. Nature Medicine *28*, 472-476. 10.1038/s41591-022-01700-x.

Gilbert, P.B., Montefiori, D.C., McDermott, A.B., Fong, Y., Benkeser, D., Deng, W., Zhou, H.,
Houchens, C.R., Martins, K., Jayashankar, L., et al. (2022). Immune correlates analysis of
the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science *375*, 43-50.
10.1126/science.abm3425.

Green, A., Curtis, H., Hulme, W., Williamson, E., Mcdonald, H., Bhaskaran, K., Rentsch, C.,
Schultze, A., Mackenna, B., Mahalingasivam, V., et al. (2022). Describing the population
experiencing COVID-19 vaccine breakthrough following second vaccination in England: a
cohort study from OpenSAFELY. BMC Medicine *20*. 10.1186/s12916-022-02422-0.

- Hall, V., Foulkes, S., Insalata, F., Kirwan, P., Saei, A., Atti, A., Wellington, E., Khawam, J.,
  Munro, K., Cole, M., et al. (2022). Protection against SARS-CoV-2 after Covid-19
  Vaccination and Previous Infection. New England Journal of Medicine *386*, 1207-1220.
- 782 10.1056/nejmoa2118691.

Hall, V.J., Foulkes, S., Charlett, A., Atti, A., Monk, E.J.M., Simmons, R., Wellington, E., Cole,
M.J., Saei, A., Oguti, B., et al. (2021a). SARS-CoV-2 infection rates of antibody-positive
compared with antibody-negative health-care workers in England: a large, multicentre,
prespective ophert study. (SIREN). The Larget 207, 1450, 1016 (20140).

786 prospective cohort study (SIREN). The Lancet 397, 1459-1469. 10.1016/s0140-

787 6736(21)00675-9.

- Hall, V.J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe,
  J., Gillson, N., Atti, A., et al. (2021b). COVID-19 vaccine coverage in health-care workers in
  England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a
  prospective, multicentre, cohort study. The Lancet *397*, 1725-1735. 10.1016/s01406736(21)00790-x.
- Kedzierska, K., and Thomas, P.G. (2022). Count on us: T cells in SARS-CoV-2 infection and
   vaccination. Cell Reports Medicine *3*, 100562. 10.1016/j.xcrm.2022.100562.
- Kent, S.J., Khoury, D.S., Reynaldi, A., Juno, J.A., Wheatley, A.K., Stadler, E., John Wherry,
  E., Triccas, J., Sasson, S.C., Cromer, D., and Davenport, M.P. (2022). Disentangling the
  relative importance of T cell responses in COVID-19: leading actors or supporting cast?
  Nature Reviews Immunology *22*, 387-397. 10.1038/s41577-022-00716-1.
- Khoury, D.S., Cromer, D., Reynaldi, A., Schlub, T.E., Wheatley, A.K., Juno, J.A., Subbarao,
  K., Kent, S.J., Triccas, J.A., and Davenport, M.P. (2021). Neutralizing antibody levels are
  highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature
  Medicine *27*, 1205-1211. 10.1038/s41591-021-01377-8.
- Kundu, R., Narean, J.S., Wang, L., Fenn, J., Pillay, T., Fernandez, N.D., Conibear, E.,
  Koycheva, A., Davies, M., Tolosa-Wright, M., et al. (2022). Cross-reactive memory T cells
  associate with protection against SARS-CoV-2 infection in COVID-19 contacts. Nature
  Communications *13*. 10.1038/s41467-021-27674-x.
- Levin, E.G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf,
  K., Mendelson, E., Ziv, A., et al. (2021). Waning Immune Humoral Response to BNT162b2
  Covid-19 Vaccine over 6 Months. New England Journal of Medicine *385*, e84.
- 810 10.1056/nejmoa2114583.
- 811 Lim, J.M.E., Tan, A.T., Le Bert, N., Hang, S.K., Low, J.G.H., and Bertoletti, A. (2022). SARS-
- 812 CoV-2 breakthrough infection in vaccinees induces virus-specific nasal-resident CD8+ and
- 813 CD4+ T cells of broad specificity. Journal of Experimental Medicine 219.
- 814 10.1084/jem.20220780.
- Liu, J., Yu, J., McMahan, K., Jacob-Dolan, C., He, X., Giffin, V., Wu, C., Sciacca, M.,
- 816 Powers, O., Nampanya, F., et al. (2022). CD8 T Cells Contribute to Vaccine Protection
- 817 Against SARS-CoV-2 in Macaques. Science Immunology, eabq7647.
- 818 10.1126/sciimmunol.abq7647.
- McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
  Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in
  rhesus macaques. Nature *590*, 630-634. 10.1038/s41586-020-03041-6.
- Mentzer, A.J., O'Connor, D., Bibi, S., Chelysheva, I., Clutterbuck, E.A., Demissie, T., Dinesh,
  T., Edwards, N.J., Felle, S., Feng, S., et al. (2022). Human leukocyte antigen alleles
  associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature
  Medicine. 10.1038/s41591-022-02078-6.
- Mohlendick, B., Ciuciulkaite, I., Elsner, C., Anastasiou, O.E., Trilling, M., Wagner, B.,
  Zwanziger, D., Jockel, K.H., Dittmer, U., and Siffert, W. (2022). Individuals With Weaker
  Antibody Responses After Booster Immunization Are Prone to Omicron Breakthrough
  Infections. Frontiers in Immunology *13*, 907343. 10.3389/fimmu.2022.907343.
- Molodtsov, I.A., Kegeles, E., Mitin, A.N., Mityaeva, O., Musatova, O.E., Panova, A.E.,
  Pashenkov, M.V., Peshkova, I.O., Alsalloum, A., Asaad, W., et al. (2022). Severe Acute

832 Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in

Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study. Clinical Infectious
 Diseases 75, e1-e9. 10.1093/cid/ciac278.

Moore, S.C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A.S., Liu, C., Dejnirattisai, W.,
Silva Reyes, L., Meardon, N., Faustini, S., et al. (2022). Evolution of long-term hybrid
immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal
observational cohort study. MedRxiv. 10.1101/2022.06.06.22275865.

Moss, P. (2022). The T cell immune response against SARS-CoV-2. Nature Immunology 23,
 186-193. 10.1038/s41590-021-01122-w.

Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jurjenson, V., Adamson, A., Haljasmagi, L.,
Rumm, A.P., Maruste, R., Karner, J., et al. (2021). Dynamics of antibody response to
BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Regional
Health Europe *10*, 100208. 10.1016/j.lanepe.2021.100208.

Nunes, M.C., Mbotwe-Sibanda, S., Baillie, V.L., Kwatra, G., Aguas, R., and Madhi, S.A.
(2022). SARS-CoV-2 Omicron Symptomatic Infections in Previously Infected or Vaccinated
South African Healthcare Workers. Vaccines *10*, 459. 10.3390/vaccines10030459.

Ogbe, A., Kronsteiner, B., Skelly, D.T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter,
H.D., Ali, M., Ali, S.-E., et al. (2021). T cell assays differentiate clinical and subclinical SARSCoV-2 infections from cross-reactive antiviral responses. Nature Communications *12*.
10.1038/s41467-021-21856-3.

Park, H.-S., Shapiro, J.R., Sitaras, I., Woldemeskel, B.A., Garliss, C.C., Dziedzic, A.,
Sachithanandham, J., Jedlicka, A.E., Caputo, C.A., Rousseau, K.E., et al. (2022). Adaptive
immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection.
JCI Insight 7. 10.1172/jci.insight.155944.

Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B.,
Otter, A., Zuo, J., and Moss, P. (2022). Extended interval BNT162b2 vaccination enhances
peak antibody generation. npj Vaccines 7. 10.1038/s41541-022-00432-w.

Payne, R.P., Longet, S., Austin, J.A., Skelly, D.T., Dejnirattisai, W., Adele, S., Meardon, N.,
Faustini, S., Al-Taei, S., Moore, S.C., et al. (2021). Immunogenicity of standard and
extended dosing intervals of BNT162b2 mRNA vaccine. Cell *184*, 5699-5714.e5611.
10.1016/j.cell.2021.10.011.

Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M.M.,
Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021). Reduced sensitivity of SARSCoV-2 variant Delta to antibody neutralization. Nature *596*, 276-280. 10.1038/s41586-02103777-9.

Rihn, S.J., Merits, A., Bakshi, S., Turnbull, M.L., Wickenhagen, A., Alexander, A.J.T., Baillie,
C., Brennan, B., Brown, F., Brunker, K., et al. (2021). A plasmid DNA-launched SARS-CoV-2
reverse genetics system and coronavirus toolkit for COVID-19 research. PLOS Biology *19*,
e3001091. 10.1371/journal.pbio.3001091.

871 Roeder, A.J., Koehler, M.A., Svarovsky, S., Jasbi, P., Seit-Nebi, A., Gonzalez-Moa, M.J.,

Vanderhoof, J., Mckechnie, D., Edwards, B.A., and Lake, D.F. (2022). SARS-CoV-2

873 Omicron Variant Infection of Individuals with High Titer Neutralizing Antibodies Post-3rd

874 mRNA Vaccine Dose. MedRxiv. 10.1101/2022.03.03.22270812.

- 875 Rovida, F., Cassaniti, I., Paolucci, S., Percivalle, E., Sarasini, A., Piralla, A., Giardina, F.,
- 876 Sammartino, J.C., Ferrari, A., Bergami, F., et al. (2021). SARS-CoV-2 vaccine breakthrough 877 infections with the alpha variant are asymptomatic or mildly symptomatic among health care
- 878 workers. Nature Communications *12*. 10.1038/s41467-021-26154-6.
- Russell, M.W., and Mestecky, J. (2022). Mucosal immunity: The missing link in
  comprehending SARS-CoV-2 infection and transmission. Frontiers in Immunology *13*,
  957107. 10.3389/fimmu.2022.957107.
- Rydyznski Moderbacher, C., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D.,
  Belanger, S., Abbott, R.K., Kim, C., Choi, J., et al. (2020). Antigen-Specific Adaptive
  Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
  Severity. Cell *183*, 996-1012.e1019. 10.1016/j.cell.2020.09.038.
- Scurr, M.J., Lippiatt, G., Capitani, L., Bentley, K., Lauder, S.N., Smart, K., Somerville, M.S.,
  Rees, T., Stanton, R.J., Gallimore, A., et al. (2022). Magnitude of venous or capillary bloodderived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature
  Communications *13*. 10.1038/s41467-022-32985-8.
- Selvavinayagam, S.T., Yong, Y.K., Tan, H.Y., Zhang, Y., Subramanian, G., Rajeshkumar,
  M., Vasudevan, K., Jayapal, P., Narayanasamy, K., Ramesh, D., et al. (2022). Factors
  Associated With the Decay of Anti-SARS-CoV-2 S1 IgG Antibodies Among Recipients of an
  Adenoviral Vector-Based AZD1222 and a Whole-Virion Inactivated BBV152 Vaccine.
- 894 Frontiers in Medicine *9*, 887974. 10.3389/fmed.2022.887974.
- Sheikh-Mohamed, S., Isho, B., Chao, G.Y.C., Zuo, M., Cohen, C., Lustig, Y., Nahass, G.R.,
  Salomon-Shulman, R.E., Blacker, G., Fazel-Zarandi, M., et al. (2022). Systemic and
  mucosal IgA responses are variably induced in response to SARS-CoV-2 mRNA vaccination
  and are associated with protection against subsequent infection. Mucosal Immunology *15*,
  799-808. 10.1038/s41385-022-00511-0.
- Skelly, D.T., Harding, A.C., Gilbert-Jaramillo, J., Knight, M.L., Longet, S., Brown, A., Adele,
  S., Adland, E., Brown, H., Chinnakannan, S., et al. (2021). Two doses of SARS-CoV-2
  vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.
  Nature Communications *12*. 10.1038/s41467-021-25167-5.
- Smoot, K., Yang, J., Tacker, D.H., Welch, S., Khodaverdi, M., Kimble, W., Wen, S., Amjad,
  A., Marsh, C., Perrotta, P.L., and Hodder, S. (2022). Persistence and Protective Potential of
  SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home
  Cohort. JAMA Network Open *5*, e2231334. 10.1001/jamanetworkopen.2022.31334.
- Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T.,
  Barclay, W., Deeks, J.J., and Lalvani, A. (2013). Cellular immune correlates of protection
  against symptomatic pandemic influenza. Nature Medicine *19*, 1305-1312.
  10.1038/nm.3350.
- Stærke, N.B., Reekie, J., Nielsen, H., Benfield, T., Wiese, L., Knudsen, L.S., Iversen, M.B.,
  Iversen, K., Fogh, K., Bodilsen, J., et al. (2022). Levels of SARS-CoV-2 antibodies among
  fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Nature
  Communications *13*. 10.1038/s41467-022-32254-8.
- Swadling, L., Diniz, M.O., Schmidt, N.M., Amin, O.E., Chandran, A., Shaw, E., Pade, C.,
   Gibbons, J.M., Le Bert, N., Tan, A.T., et al. (2022). Pre-existing polymerase-specific T ce
- Gibbons, J.M., Le Bert, N., Tan, A.T., et al. (2022). Pre-existing polymerase-specific T cells
   expand in abortive seronegative SARS-CoV-2. Nature *601*, 110-117. 10.1038/s41586-021-
- 919 04186-8.

- Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin,
  B., Phillips, E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces immunological T
  cell memory able to cross-recognize variants from Alpha to Omicron. Cell *185*, 847-
- 923 859.e811. 10.1016/j.cell.2022.01.015.
- Tartof, S.Y., Slezak, J.M., Fischer, H., Hong, V., Ackerson, B.K., Ranasinghe, O.N.,
  Frankland, T.B., Ogun, O.A., Zamparo, J.M., Gray, S., et al. (2021). Effectiveness of mRNA
  BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the
  USA: a retrospective cohort study. The Lancet *398*, 1407-1416. 10.1016/s0140-
- 928 6736(21)02183-8.
- Tay, M.Z., Rouers, A., Fong, S.W., Goh, Y.S., Chan, Y.H., Chang, Z.W., Xu, W., Tan, C.W.,
  Chia, W.N., Torres-Ruesta, A., et al. (2022). Decreased memory B cell frequencies in
  COVID-19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine *14*.
  10.15252/emmm.202115227.
- 933 Torres, I., Bellido-Blasco, J.B., Gimeno, C., Burgos, J.S., Albert, E., Moya-Malo, R.,
- 934 Gascó-Laborda, J.C., Tornero, A., Soriano, J., Meseguer-Ferrer, N., et al. (2022a).
- 935 SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm 936 after Comirnaty® COVID-19 vaccination. Journal of Medical Virology *94*, 3776-3782.
- 937 10.1002/jmv.27799.
- Torres, I., Giménez, E., Albert, E., Zulaica, J., Álvarez-Rodríguez, B., Burgos, J.S., Peiró, S.,
  Limón, R., Vanaclocha, H., Rodado, C., et al. (2022b). SARS-CoV-2 Omicron BA.1 variant
  breakthrough infections in nursing home residents after an homologous third dose of the
  COVID-19 vaccine: Looking for correlates of protection. Journal of Medical
- 942 Virology *94*, 4216-4223. 10.1002/jmv.27867.
- Tsang, T.K., Lam, K.-T., Liu, Y., Fang, V.J., Mu, X., Leung, N.H.L., Peiris, J.S.M., Leung,
  G.M., Cowling, B.J., and Tu, W. (2022). Investigation of CD4 and CD8 T cell-mediated
  protection against influenza A virus in a cohort study. BMC Medicine *20*. 10.1186/s12916022-02429-7.
- 947 UK Health Security Agency (2021). SARS-CoV-2 variants of concern and variants under 948 investigation in England; Technical Briefing 31.
- 949 <u>https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_da</u> 950 <u>ta/file/1042367/technical\_briefing-31-10-december-2021.pdf</u>.
- 951 UK Health Security Agency (2022). COVID-19 vaccination: a guide to booster vaccination for
- 952 individuals aged 18 years and over and those aged 16 years and over who are at risk.
- 953 <u>https://www.gov.uk/government/publications/covid-19-vaccination-booster-dose-</u>
- 954 resources/covid-19-vaccination-a-guide-to-booster-vaccination-for-individuals-aged-18 955 years-and-over.
- 956 van den Brink, E.N., Ter Meulen, J., Cox, F., Jongeneelen, M.A., Thijsse, A., Throsby, M.,
- 957 Marissen, W.E., Rood, P.M., Bakker, A.B., Gelderblom, H.R., et al. (2005). Molecular and
- 958 biological characterization of human monoclonal antibodies binding to the spike and
- 959 nucleocapsid proteins of severe acute respiratory syndrome coronavirus. Journal of Virology
   960 79, 1635-1644. 10.1128/JVI.79.3.1635-1644.2005.
- 961 Wall, E.C., Wu, M., Harvey, R., Kelly, G., Warchal, S., Sawyer, C., Daniels, R., Hobson, P.,
- 962 Hatipoglu, E., Ngai, Y., et al. (2021). Neutralising antibody activity against SARS-CoV-2
- 963 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet 397, 2331-2333.
- 964 10.1016/s0140-6736(21)01290-3.

- 965 Wei, J., Pouwels, K.B., Stoesser, N., Matthews, P.C., Diamond, I., Studley, R., Rourke, E.,
- 966 Cook, D., Bell, J.I., Newton, J.N., et al. (2022). Antibody responses and correlates of
- 967 protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
- 968 Nature Medicine 28, 1072-1082. 10.1038/s41591-022-01721-6.
- 969 Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y.,
- 970 Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of
- 971 SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348-
- 972 2361.e2346. 10.1016/j.cell.2021.02.037.

973

#### 974 **TABLE AND TABLE LEGEND**

#### 975 Table 1. Demographic characteristics of vaccine breakthrough cases

#### compared to controls and factors associated with vaccine breakthrough in 976

#### 977 multivariable logistic regression analysis.

	All (n=414)	Controls (n=378)	Cases (n=36)	OR <sup>1</sup> (95% CI)	p value	Adjusted OR <sup>2</sup> (95% CI)	p value
Age	-	-		-			
20-29	78 (18.8%)	70 (18.5%)	8 (22.2%)	1 (ref)	0.396	1 (ref)	0.456
30-39	86 (20.8%)	78 (20.6%)	8 (22.2%)	0.90 (0.31-2.56)		0.99 (0.34-2.86)	
40-49	109 (26.3%)	97 (25.7%)	12 (33.3%)	1.08 (0.43-2.89)		1.26 (0.49-3.44)	
50-59	97 (23.4%)	93 (24.6%)	4 (11.1%)	0.38 (0.10-1.24)		0.45 (0.11-1.51)	
60+	44 (10.6%)	40 (10.6%)	4 (11.1%)	0.88 (0.22-2.96)		1.19 (0.30-4.20)	
Sex	-	-		-			
Female	310 (74.9%)	280 (74.1%)	30 (83.3%)	1 (ref)	0.203	1 (ref)	0.078
Male	104 (25.1%)	98 (25.9%)	6 (16.7%)	0.57 (0.21-1.32)		0.46 (0.17-1.08)	
Ethnicity (self-reported	i)	•		•	•	•	•
White	298 (84.4%)	270 (83.6%)	28 (93.3%)	1 (ref)	0.265	-	-
Asian	37 (10.5%)	36 (11.1%)	1 (3.3%)	0.27 (0.02-1.32)		-	
Other	18 (5.1%)	17 (5.3%)	1 (3.3%)	0.57 (0.03-2.93)		-	
Unreported	61	55	6	-		-	
BMI (kg/m <sup>2</sup> )		•			•		
Not obese (<30)	162 (89.5%)	150 (89.8%)	12 (85.7%)	1 (ref)	0.645	-	-
Obese (≥30.0)	19 (10.5%)	17 (10.2%)	2 (14.3%)	1.47 (0.22-6.01)		-	
Unreported	233	211	22	-		-	
Vaccine type	•			•	•		•
BNT162b2	336 (81.2%)	310 (82.0%)	26 (72.2%)	1 (ref)	0.171	-	-
AZD1222	78 (18.8%)	68 (18.0%)	10 (27.8%)	1.75 (0.77-3.71)		-	
Infection history	-						÷
Naïve	244 (58.9%)	214 (56.6%)	30 (83.3%)	1 (ref)	0.001	1 (ref)	0.0009
Previous SARS-CoV-2	170 (41.1%)	164 (43.4%)	6 (16.7%)	0.26 (0.10-0.60)		0.25 (0.09-0.58)	

978 979 980 <sup>1</sup>Crude odds ratio derived from single logistic regression.

<sup>2</sup>Adjusted odds ratio derived from multiple logistic regression. The final model included and adjusted for age, sex,

and infection history.

#### 981 FIGURES AND FIGURE LEGENDS






Figure 1. Study design and comparison of antibody and T cell responses
 between cases and controls at 28 days after second vaccine dose.

984 (A) Schematic representation of study design including vaccination and 985 breakthrough infection time points. Created using Biorender.com. (B) Venn diagram 986 illustrating number of subjects with IgG and/or IFNy ELISpot measurements, by 987 case/control status. (C) Ancestral SARS-CoV-2 spike- (S), receptor binding domain-988 (RBD) and nucleoprotein- (N) specific IgG binding titre in cases (n=32) and controls 989 (n=200), as measured by MSD. Dashed lines represent threshold for positive 990 response (SARS-CoV-2 S IgG 1160 AU/mL, RDB IgG 1169 AU/mL, N IgG 3874 991 AU/mL). (D) Neutralising antibody (NAb) titres against ancestral (WT) and Delta 992 (B1.617.2) isolates in a subset of cases (n=21) and controls (n=41) measured by live 993 virus microneutralisation (LV-MN) assay. Area between IC50=40 and IC50=2560 994 (dashed black lines) corresponds to the quantitative range of the assay. IC50=5, 995 IC50=10 and IC50=5120 (solid grey lines) represent no, weak and complete 996 inhibition respectively. (E) T cell responses to peptide pools representing ancestral 997 SARS-CoV-2 S1, S2, total S (summation of S1 and S2 responses) and membrane 998 (M) and nucleoprotein (N) responses in cases (n=24) and controls (n=191), as 999 measured by IFNy ELISpot assay. (F) Correlation between anti-S IgG titre, as 1000 measured by MSD, and total ST cell responses, as measured by IFNy ELISpot, for 1001 all cases (n=24) and controls (n=144) where both parameters were measured. 1002 Dashed lines represent median value for each parameter. (G) Frequency of 1003 individuals with vaccine breakthrough (VB) in each guadrant of the graph in (F). 1004 Individuals are classified as having 'High' or 'Low' IgG and IFNy responses on the 1005 basis of whether their response is above or below median for each variable. Number 1006 of cases and controls per group are shown below the graph. Values of 0 are 1007 replaced with 1 for representation on the logarithmic scale. Orange circles represent 1008 cases, blue circles represent controls. Bars represent median of each group (C-E). 1009 Error bars represent interquartile range (C-E) or 95% confidence interval (G). Two-1010 tailed p-values derived from Mann-Whitney U tests (comparing cases to controls, (C-1011 E)), Wilcoxon matched pairs signed rank tests (comparing WT and Delta responses, 1012 (D)) or pairwise Fisher's exact tests (G) shown above linking lines. For clarity, only 1013 adjusted p values <0.1 are shown in (G). Fold change in median response shown 1014 below linking lines or in brackets, calculated as median response for controls divided 1015 by median response for cases, or median response for Delta divided by median 1016 response for WT.



#### T cell responses: ICS



1017 Figure 2. Comparison of memory B cell and T cell responses in a subset of 1018 cases and matched controls at 28 days after second vaccine dose.

1019 (A) Venn diagram illustrating the overlapping subsets of cases and controls analysed 1020 in (B-D). (B) Memory B cell responses against ancestral (WT) and Delta (B.1.617.2; 1021 AY.1, AY.2, AY.3) SARS-CoV-2 spike (S) in a subset of cases (n=10) and matched 1022 controls (n=11) measured by memory B cell IgG FluoroSpot. (C) Proportion of cells 1023 expressing IFNy, TNF or IL-2 in response to peptide pools representing ancestral 1024 (WT) or Delta (B.1.617.2) spike in the CD4+ T cell population and (D) CD8+ T cell 1025 population, in a subset of cases and matched controls (n=12 per group), as 1026 measured by intracellular cytokine staining (ICS) and flow cytometry. Populations

1027 were analysed by gating on single, live, CD3+ cells. Orange circles represent cases, 1028 blue circles represent controls. Bars represent median of each group. Error bars 1029 represent interguartile range. Paired data from the same individual are linked by grey 1030 lines. Two-tailed p-values derived from Mann-Whitney U tests (comparing cases to 1031 controls) or Wilcoxon matched pairs signed rank tests (comparing WT and Delta 1032 responses) shown above linking lines. Fold change in median response shown in 1033 brackets for comparisons where p<0.05, calculated as median response for controls 1034 divided by median response for cases, or median response for Delta divided by 1035 median response for WT.